ALSUntangled #75: Portable neuromodulation stimulator therapy
Laurel Officer,Carmel Armon,Paul Barkhaus,Morgan Beauchamp,Michael Benatar,Tulio Bertorini,Robert Bowser,Mark Bromberg,Andrew Brown,Olimpia Mihaela Carbunar,Gregory T. Carter,Jesse Crayle,Keelie Denson,Eva Feldman,Timothy Fullam,Terry Heiman-Patterson,Carlayne Jackson,Sartaj Jhooty,Danelle Levinson,Xiaoyan Li,Alexandra Linares,Elise Mallon,Javier Mascias Cadavid,Christopher Mcdermott,Tasnim Mushannen,Lyle Ostrow,Ronak Patel,Gary Pattee,Dylan Ratner,Yuyao Sun,John Sladky,Paul Wicks,Richard Bedlack
DOI: https://doi.org/10.1080/21678421.2024.2346825
2024-04-28
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Abstract:Spurred by patient interest, ALSUntangled herein examines the potential of the Portable Neuromodulation Stimulator (PoNSTM) in treating amyotrophic lateral sclerosis (ALS). The PoNSTM device, FDA-approved for the treatment of gait deficits in adult patients with multiple sclerosis, utilizes translingual neurostimulation to stimulate trigeminal and facial nerves via the tongue, aiming to induce neuroplastic changes. While there are early, promising data for PoNS treatment to improve gait and balance in multiple sclerosis, stroke, and traumatic brain injury, no pre-clinical or clinical studies have been performed in ALS. Although reasonably safe, high costs and prescription requirements will limit PoNS accessibility. At this time, due to the lack of ALS-relevant data, we cannot endorse the use of PoNS as an ALS treatment.
clinical neurology